AML
Clinical trials for AML explained in plain language.
Never miss a new study
Get alerted when new AML trials appear
Sign up with your email to follow new studies for AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to stop leukemia from coming back
Disease control Not yet recruitingThis study tests whether adding venetoclax to azacitidine as maintenance therapy helps keep acute myeloid leukemia (AML) in remission longer. About 788 people aged 14 to 74 who are already in remission after initial treatment will be randomly assigned to receive either azacitidin…
Matched conditions: AML
Phase: PHASE3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 17, 2026 06:59 UTC
-
Double punch against leukemia: CAR-T cells then stem cell transplant
Disease control Not yet recruitingThis study tests a two-step treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard chemo. First, patients receive specially engineered immune cells (CLL1 CAR-T) to attack the cancer. Then, they get a stem cell transplant from a heal…
Matched conditions: AML
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated May 17, 2026 06:52 UTC
-
New Triple-Drug attack shows promise against tough blood cancer
Disease control Not yet recruitingThis study tests a new three-drug combination (venetoclax, azacitidine, and liposomal mitoxantrone) as the first treatment for adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combo can safely improve remission rates. Participants will receive …
Matched conditions: AML
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for tough leukemia: drug combo targets resistant cells
Disease control Not yet recruitingThis early-phase trial tests a combination of two drugs (AZA and APG1252) in 52 people with high-risk acute myeloid leukemia (AML). The goal is to see if the combo is safe and can help control the disease. Participants include those whose cancer has returned or not responded to p…
Matched conditions: AML
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New app aims to guide young cancer survivors through After-Treatment challenges
Knowledge-focused Not yet recruitingThis study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if using the app helps patients feel…
Matched conditions: AML
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC